Dr. Dimitroff's most recent publications from 2005.
  1. Dimitroff CJ (corresponding author), Descheny L, Trujillo N, Kim R, Huang W, Nguyen V, Pienta K, Kutok JL, Rubin MA. Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Research, 2005; 65(13):5750-60. 
  2. Descheny L, Gainers ME, Walcheck B, Dimitroff CJ. Ameliorating skin-homing receptors on malignant T cells with a fluorosugar analog of N-acetylglucosamine: P-selectin ligand is a more sensitive target than E-selectin ligand. J. Investigative Dermatology, 2006; 126(9):2065-73.
  3. Alcaide P, King SL, Dimitroff CJ, Lim Y-C, Fuhlbrigge RC, Luscinskas FW. The 130-kDa glycoform of CD43 is an E-selectin ligand for activated Th1 cells in vitro and in delayed-type hypersensitivity reactions in vivo. J. Investigative Dermatology, 2007; 127(8):1964-72.
  4. Gainers ME, Descheny L, Barthel SB, Lui L, Wurbel M, Dimitroff CJ. Skin-homing receptors on effector leukocytes are differentially sensitive to glyco-metabolic antagonism in allergic contact dermatitis. J. Immunology, 2007;179(12):8509-18.
  5. Yamanaka K, Dimitroff CJ, Fuhlbrigge RC, Kakeda M, Kurokawa I, Mizutani H, Kupper TS. Vitamins A and D are potent inhibitors of cutaneous lymphocyte-associated antigen expression. J. Allergy Clinical Immunology, 2008; 121(1):148-57.
  6. Barthel SR, Gavino JD, Wiese GK, Jaynes JM, Siddiqui J, Dimitroff CJ. Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. J. Glycobiology, 2008; 18(10):806-17.
  7. Wiese, GK, Barthel SR, Dimitroff CJ. Analysis of Physiologic E-selectin-Mediated Leukocyte Rolling on Microvascular Endothelium. J. Visualized Experiments, 2009; (24).
  8. Barthel SR, Wiese GK, Cho J, Opperman MJ, Hays DL, Siddiqui J, Pienta KJ, Furie B, Dimitroff CJ. Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc. Natl. Acad. Sci., 2009; 106(46):19491-6.
  9. Cedeno-Laurent F, Barthel SR, Opperman MJ, Lee DM, Clark RA, Dimitroff CJ. Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation, J. Immunology, 2010;185(8):4659-72.
  10. Barthel SR, Antonopoulos A, Cedeno-Laurent F, Schaffer L, Hernandez G, Patil SA, North SJ, Dell A, Matta KL, Neelamegham S, Haslam SM, Dimitroff CJ. Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N- and O-glycans without direct incorporation. J. Biol. Chem., 2011; 286(24):21717-31.
  11. Cedeno-Laurent F, Opperman MJ, Barthel SR, Hays D, Schatton T, Zhan Q, He X, Matta KL, Supko JG, Frank MH, Murphy GF, Dimitroff CJ. Metabolic inhibition of galectin-1-binding carbohydrates accentuates anti-tumor immunity. J. Investigative Dermatology, 2012; 132(2):410-420.
  12. Cedeno-Laurent F, Opperman MJ, Barthel SR, Kuchroo VK, Dimitroff CJ. Galectin-1 triggers an immunoregulatory signature defined by IL-10 expression. J. Immunology, 2012; 188(7):3127-37.
  13. Cedeno-Laurent F, Watanabe R, Teague JE, Kupper TS, Clark RA, Dimitroff CJ. Galectin-1 inhibits the viability, proliferation and Th1 cytokine production of non-malignant T cells in patients with leukemic cutaneous T cell lymphoma. BLOOD, 2012; 119(15):3534-8.
  14. Barthel SR, Hays DL, Yazawa EM, Opperman M, Walley KC, Nimrichter L, Burdick MM, Gillard BM, Moser MT, Pantel K, Foster BA, Pienta KJ and Dimitroff CJ. Definition of molecular determinants of prostate cancer cell bone extravasation. Cancer Research, 2013; 73(2):942-952. 
  15. Li J, Guillebon AD, Hsu J-W, Barthel SR, Dimitroff CJ, Lee Y-F and King MR. Human fucosyltransferase 6 enables prostate cancer metastasis to bone. British J. Cancer, 2013;109(12):3014-22.
  16. Burdick MM, Reynolds NM, Martin EW, Hawes JV, Carlson GE, Cuckler CM, Bates MC, Barthel SR, Dimitroff CJ. Isolation and characterization of chimeric human Fc-expressing proteins using protein A membrane adsorbers and a streamlined workflow. J. Visualized Experiments, 2014; 8;(83). 
  17. Yazawa EM, Geddes-Sweeney JE, Cedeno-Laurent F, Walley KC, Barthel SR, Opperman MJ, Liang J, Lin JY, Schatton T, Laga AC, Mihm MC, Qureshi AA, Widlund HR, Murphy GF and Dimitroff CJ. Melanoma cell galectin-1 ligands functionally correlate with malignant potential. J. Investigative Dermatology, 2015; 135(7):1849-62.
  18. Geddes Sweeney J, Liang J, Aristotelis A, Giovannone N, Kang S, Mondala T, Head SR, King SL, Tani Y, Brackett D, Dell A, Murphy GF, Haslam SM, Widlund HR and Dimitroff CJ. Loss of GCNT2/I-branched glycans enhances melanoma growth and survival. Nature Communications, 2018; 9(1):3368.
  19. Giovannone N, Liang J, Aristotelis A, Geddes-Sweeney J, King SL, Pochebit SM, Neil Bhattacharyya N., Dell A, Widlund HR, Haslam SM and Dimitroff CJ. Galectin-9 suppresses B cell receptor signaling and is regulated by I-branching of N-glycans. Nature Communications, 2018; 9(1):3287.
  20. Giovannone N, Antonopoulos A, Liang J, Geddes Sweeney J, Kudelka MR, King, SL, Lee GS, Cummings RD, Dell A, Barthel SR, Widlund HR, Haslam SM, Dimitroff CJ. Human B cell differentiation is characterized by progressive remodeling of O-linked glycans. Frontiers in Immunology, 2018; 9:2857.
  21. Mendoza M, Li D, Ballesteros A, Blois SM, Abernathy K, Dimitroff CJ, Zmuda J, Panico M, Dell A, Vasta GR, Haslam SM, Dveksler G. Glycan characterization of pregnancy-specific glycoprotein 1 and its identification as a Galectin-1 ligand. Glycobiology, 2020;30(11):895-909.
  22. Chakraborty A, Staudinger C, King SL, Clemente Erickson F, Lau LS, Bernasconi A, Luscinskas FW, Perlyn C, and Dimitroff CJ. Galectin-9 bridges human B cell – vascular endothelial cells
    while programming regulatory pathways. Journal of Autoimmunity. 2020;117:102575.
  23. Chakraborty A, Mohammed NBB, Bernasconi A, Dimitroff CJ. Analysis of galectin-binding receptors on B cells. Methods in Molecular Biology, 2021, In press.
  24. Perez M, Asmi Chakraborty A, Lau LS, Mohammed NBB, Dimitroff CJ. Melanoma-associated glycosyltransferase GCNT2 as an emerging biomarker and therapeutic target. British Journal of Dermatology, 2021, Mar 3. DOI: 10.1111/bjd.19891. Online ahead of print..